ertugliflozin / sitagliptin

This medicine is authorised for use in the European Union.


Steglujan is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes. It is used together with diet and exercise in the following patients:

  • patients whose blood glucose levels are not satisfactorily controlled with the diabetes medicines metformin and/or a sulphonylurea, in combination with either ertugliflozin or sitagliptin;
  • patients who are already taking ertugliflozin and sitagliptin as separate tablets.

Steglujan contains the active substances ertugliflozin and sitagliptin.

This EPAR was last updated on 19/09/2023

Authorisation details

Product details
Agency product number
Active substance
  • ertugliflozin l-pyroglutamic acid
  • sitagliptin phosphate monohydrate
International non-proprietary name (INN) or common name
  • ertugliflozin
  • sitagliptin
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

18/09/2023 Steglujan - EMEA/H/C/004313 - IB/0025/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Drugs used in diabetes

  • Combinations of oral blood glucose lowering drugs

Therapeutic indication

Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

  • when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control.
  • in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.

Assessment history

How useful was this page?

Add your rating